Could a drug combo spare some patients from stem cell transplant?
NCT ID NCT04991103
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 trial is testing whether a powerful four-drug combination can make multiple myeloma or amyloidosis disappear at a genetic level, allowing patients to safely postpone or avoid a stem cell transplant. About 40 newly diagnosed adults will receive the drug therapy first; those who achieve a deep response will skip transplant, while others will proceed to transplant. The goal is to see if this personalized approach can reduce the need for intensive transplant without harming outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab, bortezomib, lenalidomide, dexamethasone, cyclophosphamide (combination drug therapy)
What this could lead to
If successful, this could show that some patients with multiple myeloma or amyloidosis can safely delay or avoid a stem cell transplant by first achieving a very deep response to drug therapy.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The approach may not work for everyone, and the drug combination has side effects like infection risk and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.